Meet the Ribometrix team, where every individual is valued as part of a collaborative community sharing a common focus on advancing the field of modulating RNA biology to discover and develop transformative small-molecule drugs.
Company
A Company on the Cutting Edge
Ribometrix is a drug-discovery company leading a new paradigm in small molecule therapeutics that modulate RNA biology. Our industry-leading drug discovery platform enables us to leverage RNA structure determination and state-of-the art RNA tools and technologies to directly target and modulate RNA biology.
A Unique Drug Discovery Engine
We employ three independent but related strategies to develop small molecule therapeutics. (1) Direct targeting of complex RNA structures, (2) disrupting RNA/RNA-binding protein interactions, and (3) targeting an RNA for degradation. We believe our commitment to this new paradigm will deliver innovative new therapies to patients.
-
Our Mission
Leveraging RNA expertise to discover and develop transformative small-molecule drugs.
-
Our Vision
We are committed to improving the lives of patients and families by developing therapies through innovative science.
-
Our Values
Collaboration
We seek help when we need it and provide support when we can.
Integrity
We act with respect, sincerity, and transparency.
Innovation
We create with intent.
Empowerment
We are accountable for our actions and results.
Resilience
We conquer with persistence and adaptability.
Community
We foster camaraderie with shared purpose, values, and goals.
Our People
Ribometrix Leadership & Team
Careers
Join Our Team
We are a team of individuals driven by the spirit of innovation, collaboration, empowerment, and integrity who are committed to the goal of helping patients with our novel therapeutic approach.
If you are looking for an opportunity to pioneer new science, collaborate with great people, and ultimately help those in need, then Ribometrix may be the place for you.
Our Latest Updates
View All News-
Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
-
Ribometrix To Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024
-
Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024